Velnacrine for the treatment of Alzheimer's disease: A double-blind, placebo-controlled trial

F. P. Zemlan, D. G. Folks, B. J. Goldstein, G. Gottlieb, R. F. Holub, R. D. Linden, R. A. Margolin, R. W. Richter, W. F. Speakman, R. L. Strub

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The present study examines the safety and efficacy of the centrally acting cholinesterase inhibitor, velnacrine, in treating the cognitive symptoms of Alzheimer's disease. Seven hundred thirty-five patients with mild-to-severe Alzheimer's disease were treated in a double-blind, placebo-controlled study. Following the screen visit, patients were treated with velnacrine (10, 25, 50 and 75 mg t.i.d.) or placebo in a double-blind dose-ranging study to identify velnacrine-responsive patients and their best dose. Following placebo washout velnacrine responsive patients were randomly assigned to their best dose of velnacrine (N = 153) or placebo (N = 156) in a six week double-blind dose-replication study. Primary efficacy measures were the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS) and the Physician's Clinical Global Impression of Change. Statistically significant improvement was observed in both primary efficacy measures in velnacrine-treated patients during the dose-replication study. Velnacrine patients scored better on the cognitive subscale of the ADAS than placebo patients (P < 0.001), with patients receiving the highest velnacrine dose averaging a 4.1-point improvement with respect to screen values. Clinical Global Impression of Change scores of velnacrine-treated patients were significantly improved at the end of the 6 weeks of treatment when compared to those of placebo patients (P < 0.05). The most common side effect was asymptomatic elevation in liver transaminase levels, which occurred among 29% of patients. These data suggest that velnacrine produces modest clinical improvement in a subset of patients with mild-to-severe Alzheimer's disease.

Original languageEnglish
Pages (from-to)1105-1116
Number of pages12
JournalJournal of Neural Transmission
Volume103
Issue number8-9
DOIs
StatePublished - Nov 26 1996
Externally publishedYes

Fingerprint

Alzheimer Disease
Placebos
Therapeutics
velnacrine
Neurobehavioral Manifestations
Cholinesterase Inhibitors
Transaminases
Physicians
Safety
Liver

Keywords

  • Alzheimer's disease
  • Cholinesterase inhibitor
  • Psychparmacology
  • Velnacrine

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Zemlan, F. P., Folks, D. G., Goldstein, B. J., Gottlieb, G., Holub, R. F., Linden, R. D., ... Strub, R. L. (1996). Velnacrine for the treatment of Alzheimer's disease: A double-blind, placebo-controlled trial. Journal of Neural Transmission, 103(8-9), 1105-1116. https://doi.org/10.1007/BF01291795

Velnacrine for the treatment of Alzheimer's disease : A double-blind, placebo-controlled trial. / Zemlan, F. P.; Folks, D. G.; Goldstein, B. J.; Gottlieb, G.; Holub, R. F.; Linden, R. D.; Margolin, R. A.; Richter, R. W.; Speakman, W. F.; Strub, R. L.

In: Journal of Neural Transmission, Vol. 103, No. 8-9, 26.11.1996, p. 1105-1116.

Research output: Contribution to journalArticle

Zemlan, FP, Folks, DG, Goldstein, BJ, Gottlieb, G, Holub, RF, Linden, RD, Margolin, RA, Richter, RW, Speakman, WF & Strub, RL 1996, 'Velnacrine for the treatment of Alzheimer's disease: A double-blind, placebo-controlled trial', Journal of Neural Transmission, vol. 103, no. 8-9, pp. 1105-1116. https://doi.org/10.1007/BF01291795
Zemlan FP, Folks DG, Goldstein BJ, Gottlieb G, Holub RF, Linden RD et al. Velnacrine for the treatment of Alzheimer's disease: A double-blind, placebo-controlled trial. Journal of Neural Transmission. 1996 Nov 26;103(8-9):1105-1116. https://doi.org/10.1007/BF01291795
Zemlan, F. P. ; Folks, D. G. ; Goldstein, B. J. ; Gottlieb, G. ; Holub, R. F. ; Linden, R. D. ; Margolin, R. A. ; Richter, R. W. ; Speakman, W. F. ; Strub, R. L. / Velnacrine for the treatment of Alzheimer's disease : A double-blind, placebo-controlled trial. In: Journal of Neural Transmission. 1996 ; Vol. 103, No. 8-9. pp. 1105-1116.
@article{f6dba793b4ec49da83fb72faba987106,
title = "Velnacrine for the treatment of Alzheimer's disease: A double-blind, placebo-controlled trial",
abstract = "The present study examines the safety and efficacy of the centrally acting cholinesterase inhibitor, velnacrine, in treating the cognitive symptoms of Alzheimer's disease. Seven hundred thirty-five patients with mild-to-severe Alzheimer's disease were treated in a double-blind, placebo-controlled study. Following the screen visit, patients were treated with velnacrine (10, 25, 50 and 75 mg t.i.d.) or placebo in a double-blind dose-ranging study to identify velnacrine-responsive patients and their best dose. Following placebo washout velnacrine responsive patients were randomly assigned to their best dose of velnacrine (N = 153) or placebo (N = 156) in a six week double-blind dose-replication study. Primary efficacy measures were the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS) and the Physician's Clinical Global Impression of Change. Statistically significant improvement was observed in both primary efficacy measures in velnacrine-treated patients during the dose-replication study. Velnacrine patients scored better on the cognitive subscale of the ADAS than placebo patients (P < 0.001), with patients receiving the highest velnacrine dose averaging a 4.1-point improvement with respect to screen values. Clinical Global Impression of Change scores of velnacrine-treated patients were significantly improved at the end of the 6 weeks of treatment when compared to those of placebo patients (P < 0.05). The most common side effect was asymptomatic elevation in liver transaminase levels, which occurred among 29{\%} of patients. These data suggest that velnacrine produces modest clinical improvement in a subset of patients with mild-to-severe Alzheimer's disease.",
keywords = "Alzheimer's disease, Cholinesterase inhibitor, Psychparmacology, Velnacrine",
author = "Zemlan, {F. P.} and Folks, {D. G.} and Goldstein, {B. J.} and G. Gottlieb and Holub, {R. F.} and Linden, {R. D.} and Margolin, {R. A.} and Richter, {R. W.} and Speakman, {W. F.} and Strub, {R. L.}",
year = "1996",
month = "11",
day = "26",
doi = "10.1007/BF01291795",
language = "English",
volume = "103",
pages = "1105--1116",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer Verlag",
number = "8-9",

}

TY - JOUR

T1 - Velnacrine for the treatment of Alzheimer's disease

T2 - A double-blind, placebo-controlled trial

AU - Zemlan, F. P.

AU - Folks, D. G.

AU - Goldstein, B. J.

AU - Gottlieb, G.

AU - Holub, R. F.

AU - Linden, R. D.

AU - Margolin, R. A.

AU - Richter, R. W.

AU - Speakman, W. F.

AU - Strub, R. L.

PY - 1996/11/26

Y1 - 1996/11/26

N2 - The present study examines the safety and efficacy of the centrally acting cholinesterase inhibitor, velnacrine, in treating the cognitive symptoms of Alzheimer's disease. Seven hundred thirty-five patients with mild-to-severe Alzheimer's disease were treated in a double-blind, placebo-controlled study. Following the screen visit, patients were treated with velnacrine (10, 25, 50 and 75 mg t.i.d.) or placebo in a double-blind dose-ranging study to identify velnacrine-responsive patients and their best dose. Following placebo washout velnacrine responsive patients were randomly assigned to their best dose of velnacrine (N = 153) or placebo (N = 156) in a six week double-blind dose-replication study. Primary efficacy measures were the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS) and the Physician's Clinical Global Impression of Change. Statistically significant improvement was observed in both primary efficacy measures in velnacrine-treated patients during the dose-replication study. Velnacrine patients scored better on the cognitive subscale of the ADAS than placebo patients (P < 0.001), with patients receiving the highest velnacrine dose averaging a 4.1-point improvement with respect to screen values. Clinical Global Impression of Change scores of velnacrine-treated patients were significantly improved at the end of the 6 weeks of treatment when compared to those of placebo patients (P < 0.05). The most common side effect was asymptomatic elevation in liver transaminase levels, which occurred among 29% of patients. These data suggest that velnacrine produces modest clinical improvement in a subset of patients with mild-to-severe Alzheimer's disease.

AB - The present study examines the safety and efficacy of the centrally acting cholinesterase inhibitor, velnacrine, in treating the cognitive symptoms of Alzheimer's disease. Seven hundred thirty-five patients with mild-to-severe Alzheimer's disease were treated in a double-blind, placebo-controlled study. Following the screen visit, patients were treated with velnacrine (10, 25, 50 and 75 mg t.i.d.) or placebo in a double-blind dose-ranging study to identify velnacrine-responsive patients and their best dose. Following placebo washout velnacrine responsive patients were randomly assigned to their best dose of velnacrine (N = 153) or placebo (N = 156) in a six week double-blind dose-replication study. Primary efficacy measures were the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS) and the Physician's Clinical Global Impression of Change. Statistically significant improvement was observed in both primary efficacy measures in velnacrine-treated patients during the dose-replication study. Velnacrine patients scored better on the cognitive subscale of the ADAS than placebo patients (P < 0.001), with patients receiving the highest velnacrine dose averaging a 4.1-point improvement with respect to screen values. Clinical Global Impression of Change scores of velnacrine-treated patients were significantly improved at the end of the 6 weeks of treatment when compared to those of placebo patients (P < 0.05). The most common side effect was asymptomatic elevation in liver transaminase levels, which occurred among 29% of patients. These data suggest that velnacrine produces modest clinical improvement in a subset of patients with mild-to-severe Alzheimer's disease.

KW - Alzheimer's disease

KW - Cholinesterase inhibitor

KW - Psychparmacology

KW - Velnacrine

UR - http://www.scopus.com/inward/record.url?scp=10544234610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10544234610&partnerID=8YFLogxK

U2 - 10.1007/BF01291795

DO - 10.1007/BF01291795

M3 - Article

C2 - 9013398

AN - SCOPUS:10544234610

VL - 103

SP - 1105

EP - 1116

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 8-9

ER -